Otsuka Corporation (TYO:4768)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.67T +42.5% |
| Revenue (ttm) | 1.39T +12.3% |
| Net Income | 67.16B +10.7% |
| EPS | 176.46 +10.3% |
| Shares Out | 379.20M |
| PE Ratio | 24.97 |
| Forward PE | 24.66 |
| Dividend | 105.00 (2.38%) |
| Ex-Dividend Date | Dec 29, 2026 |
| Volume | 2,543,800 |
| Open | 4,436.00 |
| Previous Close | 4,506.00 |
| Day's Range | 4,364.00 - 4,486.00 |
| 52-Week Range | 2,697.00 - 4,518.00 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 3,889.17 (-11.73%) |
| Earnings Date | Oct 30, 2026 |
About Otsuka
Otsuka Corporation, together with its subsidiaries, provides information services in Japan. It operates through System Integration Business, and Service and Support Business segments. The System Integration Business segment offers computers, copiers, and communication equipment and software, as well as consigned software development and other activities. This segment also provides system services, such as consulting, system design and development, transport and installation work, and network construction services. The Service and Support Busine... [Read more]
Financial Performance
In 2025, Otsuka's revenue was 1.32 trillion, an increase of 19.42% compared to the previous year's 1.11 trillion. Earnings were 64.30 billion, an increase of 20.24%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for 4768 stock is "Buy." The 12-month stock price target is ¥3,889, which is a decrease of -11.73% from the latest price.
News
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis,...
Vera Makes A Bullish Move — Times Three. Will It Hold Up To Competition?
Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex Pharmaceuticals.
Otsuka Quarterly report: Q2 2026
Otsuka has published its Q2 2026 quarterly earnings report on August 3, 2026.
Otsuka Slides: Q2 2026
Otsuka has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Otsuka Quarterly report: Q1 2026
Otsuka has published its Q1 2026 quarterly earnings report on April 30, 2026.
Otsuka Slides: Q1 2026
Otsuka has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Otsuka Quarterly report: Q4 2025
Otsuka has published its Q4 2025 quarterly earnings report on February 2, 2026.
Otsuka Slides: Q4 2025
Otsuka has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 2, 2026.
Otsuka Quarterly report: Q3 2025
Otsuka has published its Q3 2025 quarterly earnings report on October 31, 2025.
Otsuka Slides: Q3 2025
Otsuka has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 31, 2025.
Esperion announces Otsuka submitted NDA to Japanese MHLW for bempedoic acid
Esperion (ESPR) announced that Otsuka Pharmaceutical (OSUKF) has submitted a New Drug Application, NDA, to the Japanese Ministry of Health, Labour and Welfare, MHLW, for the manufacture and sale of…
Otsuka Corp. upgraded to Buy from Neutral at Citi
Citi analyst Mitsunobu Tsuruo upgraded Otsuka Corp. to Buy from Neutral with a price target of 7,200 yen, up from 6,000 yen. The analyst sees sustained earnings growth for the…
Otsuka Corp. initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Hiroto Segawa initiated coverage of Otsuka Corp. with an Underweight rating and 3,800 yen price target. For Otsuka, its main customers are "likely to lack vigor" with…